CNR1 and myeloid sarcoma: Cannabinoid-based treatment that acts both on classical targets of the endocannabinoid system as CB1R/CB2R but also on PPAR-γ and GPR5 receptors that modulate neuroinflammation can be beneficial in MS on a case by case basis [64,70,71,72,78,82,83].